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Chapter One 
Introduction 
1.1 Purpose of Study and Significance 
Cancer is the No.2 cause of deaths in the U.S and also in other countries worldwide after 
heart diseases. For 2018 ‘The American Cancer Society’ predicted that 1.7 million people will be 
diagnosed with cancer and that more than 609,000 would die of the disease. 1 The patients who 
lost their life to cancer were known to be detected with higher stages of cancer, this meant that 
there is a better chance of healing or surviving if the disease was detected at an earlier stage. So, 
with these statistics with about 35.8% of the patients detected losing their lives to the disease, 
diagnosing cancer at early stages before it could spread which in medical terms is be metastasized 
and become incurable accounting for higher stages of cancer will have a significant impact on the 
survival rates. This growing concern brought into focus the detection or diagnosis and the 
treatment of cancer into the limelight. Diagnostic testing involves tests and procedures that 
confirm the presence and also help identify the correct type of tumor, its location, extent of its 
spread and the stage.2 Diagnostics thus plays a very important role throughout cancer treatment 
because with cancer it’s not just the initial detection of cancer that is important but also the fact 
that it needs to be monitored accurately throughout the course of treatment and even after that. 
Bearing this in mind researchers put in years of work in developing some diagnostic tests and 
tools which include lab tests (Blood, urine etc. examination)(body fluids), Biopsy, Imaging tests, 
Endoscopy, genetic tests etc. as diagnostic tools for cancer.2 Other techniques available apart 
from the ones just mentioned were based on cell morphology and microscopy.3 ,4  All of these 
techniques were least sensitive to the quantification of cancer and gave limited information on  
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 the onset of the cancer and were thus said to be inconclusive.3, 4 All of these existing tests having 
said to be inconclusive it was observed that the death rate due to the disease was still high.  In 
order to stop this battle between life and death it was concluded that we needed some sensitive, 
accurate methods for the diagnosis wherein the cancer could be detected at the very initial stages 
of the disease and could be accurately quantitated. Also, the then existing tests were expensive 
and so it was important to make the tests cost effective making it affordable to all. This would 
definitely help the survival rates go up. There also grew a need for point of care testing which 
acted as another driving force for better and conclusive tests for the disease that were cheaper 
and thus easily made available. With this view as an alternate to the above mentioned diagnostic 
tools for cancer there were developed tests wherein the patient samples included body fluids to 
test for levels of proteins that were related to cancer.5,6 These proteins act as indicators for 
cancer and quantitating them could help associate with the different stages of the disease.7 This 
research was a breakthrough for the world of clinical diagnostics.  With this understanding many 
biosensors were developed which are still being used in order to detect and quantitate these 
proteins which are said to act as biomarkers for particular types of cancer. Biosensors are the 
most critical component of Point of care testing and diagnostics and are said to be directly 
responsible for the bioanalytical performance of an assay.8 The advantage of biosensors was that 
they were small, cost effective, easy to handle, used the simplest technology and above all were 
highly sensitive and gave accurate results.  
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1.2.  Point of care detection system 
 
Figure 1.1 Point- of- care- diagnostics general overview- Ushering in a paradigm shift in 
healthcare9 
 
Over years of research with the aim to detect and monitor cancer at early stages 
accurately there developed a need to provide point of care testing which contrasts with the 
historical pattern in which testing was wholly or mostly confined to the medical laboratory.10 
Point of care testing is also generally called bedside testing.10 This technology was meant to 
provide to the patient easy ways of diagnostic testing at or near the point of care. This could be 
in the physician’s office, an ambulance, home, fields or in the hospital in contrast to diagnosis 
being confined to the medical laboratory.11 Clinical diagnostics in medical laboratories requires 
the samples to be carried to the testing lab, which increased the wait times, required more 
administration and also increased the cost of the testing.12, 13,14  Thus the concept of Point of care 
testing devices was thought of to provide quick, accurate results at any time and place. A good 
example of this adaptation is that for years ELISA that is enzyme linked immunosorbent assays 
has been the gold standard for the detection of proteins.15,16,14 However, the method involves  
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dealing with large sample and reagent volumes with longer assay times to obtain final results and 
is also labor intensive. Additionally, these methods lacked sensitivity. Several techniques have 
been associated with these tests. Mass Spectrometry is one technique that is also being used for 
the detection of proteins which is very sensitive with detection limits ranging from 1-100 pg mL-
1 in serum samples.14,17 However, this technique is very expensive and requires high expertise. 
The driving force for POCT was to bring the test conveniently and immediately to the patient. 
This helped increase the likelihood that the patient, physician and the care team would receive 
the results quicker which in turn allows for immediate decisions related to care and treatment of 
the disease.10 POCT was accomplished with the development of transportable, portable and 
handheld instruments. So, point of care testing devices have the advantage of being handheld 
devices and thus were portable, they required very low amounts of sample and reagents and 
most importantly could also further detect multiple biomarker proteins. Examples of these 
devices would be the Blood Glucose meter which could be in the form of a hand held device or 
the new electrochemical lens that can test and monitor the level of glucose in the blood12 
and  test kits (e.g., CRP, HBA1C, Homocystein, HIV salivary assay, etc.).10 These biosensors were 
based on simple detection techniques like fluorescence, electrochemiluminescence, surface 
plasmon resonance etc.17, 13, 18, 19 Electrochemistry based biosensor devices worked best fulfilling 
all the above requirements.14 Cheaper faster and smarter POCT devices so far developed have 
increased the adaptation to POCT approaches making it cost effective for many diseases of which 
one is cancer.  
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1.3 Cancer Biomarkers- Detection of Proteins 
 
An approach to the achievement of some speedy, highly efficient and informative data 
using precise clinical measurement tools in order to determine the progression of a disease and 
the effects of interventions like drugs administered during treatment, or surgery or vaccines etc. 
has been of interest to researchers in recent times. These approaches include gene analysis or 
assessing some biological parameter which is referred to as a biomarker.20 
The term biomarker can vaguely be defined as “a characteristic that is measured and 
evaluated as an indicator of a normal biological process, or some pharmacologic responses to a 
treatment or therapeutic intervention that is nothing but a diseased condition”.20 Biomarkers 
that are specific to a diseases include some physical symptoms, proteins secreted by mutated 
DNA and RNA’s, some natural processes like cell death or cell proliferation , and small molecule 
like glucose or cholesterol concentration in the serum, etc.21 The advancements in proteomics 
discovered that patients could be screened for cancer without having to undergo any invasive 
tests 5, 6 by just analyzing body fluids to check for proteins that act as cancer biomarkers. 
Biomarkers especially for cancer can be a molecule which may be secreted by the tumor or may 
be a response of the body to the presence of cancerous cells. 22, 23, 24, 25 Cancer biomarkers can 
be used for diagnosis- defining which type of cancer it might be, prognosis- defining if it is likely 
to develop cancer and lastly epidemiology - dealing with the incidence, distribution and the 
possible control of the cancer.25 The biomarkers used for the diagnosis, prognosis and 
epidemiology are genetic, epigenetic, proteomic, glycomic and imaging biomarkers.25 Biomarkers 
that are detected in biofluids like blood or serum means those dealing with the quantitation of 
the marker in order to predict the risk and stage of cancer, help in early screening, and also   
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monitoring the course of treatment and beyond. 22, 26 There are many biomarkers available that 
have been approved by the FDA in the United states.25, 7 A major drawback with the use of 
biomarkers was that a single marker is indicative of more than one type of cancer. For example 
Prostate Specific Antigen is an important tumor marker for Prostate cancer, however it has low 
specificity as its concentration can be high in both benign conditions and malignant disease 
conditions.20 Therefore, in effort to rule out such possibility it was concluded that a panel of 
biomarkers would work best in place of a single one.5, 14, 27, 28, 26 Also going from patient to patient 
a single biomarker can be poorly expressed in the blood stream of an individual and therefore 
may result in false positive and false negatives.29 Using a panel of biomarkers where the 
biomarker levels are elevated helps to get rid of these false positive and false negative results. 
This approach can help in the early detection of cancer, as well as in improvement in patient 
prognosis and care. The biomarkers that make up the panel thus need to have excellent 
specificity, which means the ability of the assay to rule out the condition when it is absent and 
also excellent sensitivity which is the ability of the assay to identify a condition when it is present. 
These parameters are thus important to avoid misdiagnosis giving false positives or false 
negatives. The existing biomarkers thus require validating, so that fully validated biomarkers can 
be used as diagnostic, prognostic and predictive markers especially when used in panels.21 With 
this the development of accurate, sensitive, cheap automated devices for the detection of 
multiprotein biomarkers from patient samples at point of care is the what is being aimed at today. 
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1.4 Electrochemistry based detection of proteins 
Biosensors that are based on electrochemistry combine the sensitivity of an 
electroanalytical method to the bio-selectivity of a biological component that is being detected 
in the process.30 The biological component (proteins, enzymes, nuclei acids, cells, antibodies, 
tissues or receptors) recognizes the analyte from the biological sample thus resulting either in 
catalytic or binding event that produces an electrical signal, this signal is directly proportional to 
the concentration of the analyte under study.30 With the various types of electrochemical 
biosensors, the detection of chemical and biological components might involve measuring a 
change in response to current, potential, capacitance, conductance etc. at electrode interfaces.13, 
31, 32, 30 These thus provide a way of measuring the content of a biological component to be 
detected which is attached to an electrode transducer by direct conversion of a biological event  
to an electronic signal 31,30 Traditional techniques that have been used in the past include cyclic 
voltammetry, chronoamperometry, chronopotentiometry, impedance spectroscopy and various 
field effect transistor based methods.31 On the other hand with the growth in science the newer 
techniques include nanowire or magnetic nanoparticle- based biosensing these improvements 
have helped give great sensitivity and selectivity.31, 30  The steps additional to recognition of the 
analyte in the biological samples include signal transduction and readout.32 Since these 
electrochemical biosensors deal with electrochemical change that takes place at the surface of 
the electrode, the material with which the electrode transducer has been made plays a critical 
role in the construction of the sensor that aims at detecting the target molecules using various 
analytical concepts. 13, 32, 31, 30 Common electrode transducers include amperometric, 
potentiometric, conductometric and impedance. 13, 32, 31, 30 Potentiometric and amperometric   
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transducers are most commonly used.  In potentiometric devices analytical information is 
obtained by converting the biorecognition process into a potential signal which is connected to 
using ion selective electrodes for this purpose. While in Amperometric transducers a constant 
potential is applied and in turn the current associated with the reaction taking place that is 
oxidation or reduction of the electroactive species involved is monitored. Amperometric sensors 
offer greater sensitivity and a wider linear dynamic range of operation making them most suitable 
for protein detection.13, 32, 31, 30  
Sensors that are based on sandwich immunoassay in combination with microfluidics have 
proven to be the best this far. In these cases, the capture antibodies are immobilized onto the 
surface of the reference electrode. The antigen or sample containing the component to be 
detected and the detection antibodies attached to a label are serially flown in with the help of 
micropumps. This completes the sandwich immunoassay. These altogether give excellent 
detection limits as low as pg/mL range.  
 
1.5. Nanomaterial platforms used for Electrochemical Detection 
Nanoscale materials have unique properties and their use in synergy with electrochemical 
biosensors has made it possible to measure specific electrical properties more accurately and 
with better sensitivity in combination with electrode transducers. 31 Nanomaterials have high 
surface to volume ratios which makes their electrical properties more prone to external 
influences.31 These nanomaterial platforms used on the electrode surface first began in the early 
1990’s.21, 33, 34 In those times these platforms contributed only to the increase in electrochemical 
signal through the increase of the surface-to- volume ratios. Later it was seen that additionally   
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these platforms were capable of lowering the detection limits and showed higher sensitivity to 
analytes.34  Some of the nanomaterial objects that are currently being used include nanowires, 
carbon nanotubes, nanoparticles, nanorods etc.31 Having said this it can be concluded that the 
detection ability of a biosensor depends on the specific electrode, the material with which the 
electrode has been made and its surface modification. The electrodes are modified using the 
aforementioned nanomaterial objects.  
1.5.1. Carbon nanotubes: are known for their excellent mechanical and electrical- 
conductivity properties making them most suitable for electroanalytical sensing. 35 Single 
walled carbon nanotubes are nothing but a sheet of graphene rolled into a single walled 
cylinder with a nanometer diameter. 35These are entirely made up of sp2 hybridized carbon 
which gives it special characteristics of higher tensile strength, chemical stability and 
electrical conductivity.35 In order to enhance the selectivity and specificity of these carbon 
nanotubes they need to be functionalized either with nanoparticles, biomolecules or other 
molecules are usually functionalized before they are used.35 In the past our lab has used 
single walled carbon nanotubes in biosensors dealing with sandwich immunoassays. In such 
cases the nanotubes are Carboxylated or Amine functionalized as this is suitable for 
conjugation with biomolecules. In recent times SWCNTs have been used in ECL based assay. 
They are known to increase the surface area of the electrode in order to increase the 
number of capture antibodies that are immobilized on their surface. It has been seen that 
there is a 10-15fold increase in the surface concentrations of primary antibodies attached 
to them in the process.   
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1.5.2. Similarly, nanoparticles are used for ultrasensitive detection of proteins by 
researchers overall. These nanoparticles too require functionalization to enhance their 
selectivity and specificity for their attachment to biomolecules desired. A variety of 
particles have been used so far. Gold nanoparticles, magnetic bead nanoparticles, 
luminescent core nanoparticles etc. Ultrasensitive detection of proteins used in our lab set 
to use densely packed films of 5 nm Gold nanoparticles (AuNP).36 The AuNPs used were 
protected by a layer of glutathione molecules that made them similar to SWCNTs thus 
providing the end carboxylic group allowing for the attachment of antibody. 36 Currently 
nanobubbles are being used for ultrasound imaging. These were directly coupled to a 
handheld transrectal ultrasound and photoacoustic device offering a more effective, 
integrated and less invasive technique to image. Similarly, Gold nanoparticles are being 
used to enhance the light scattering in endoscopic techniques. Magnetic nanoparticles 
work in a similar fashion singularly or in combination with gold nanoparticles.  
In a different case comparison between SWCNT and AuNP platforms was performed 
for the detection of IL-6 protein cancer biomarker, and it was seen that AuNPs achieved 
lower detection limits of 10 pg mL-1 which was 3 fold better than that achieved by SWCNTs 
sensor used for the same.36 With this the current sensors were developed combining 
SWCNT and nanoparticles to expand for further multiplexed detection of proteins on sensor 
arrays.   
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1.5. 3D Printed devices and their role in electrochemical based protein detection/ 
Microfluidic Electrochemical detection of proteins 
Immunosensors that are based on microfluidics offer remarkable features for POC 
detection such as they require lower sample and reagent volumes, higher surface to volume 
ratios reducing the total assay times, and automation.36, 34 In addition the ability of such 
immunosensors to integrate gives better performance. The first microfluidic device was made of 
glass and was used in a magnetic bead- based immunoassay giving detection limits of 50 ng mL-
1.37 In addition to the use of glass for fabricating the microfluidic devices polymers such as 
poly(dimethyl siloxane), or PDMS which is a soft elastomer and optically transparent were 
used.38, 39 Currently 3D printing technology is gaining importance with respect to making 
microfluidic devices for sensors that are being used in POC testing and diagnostics.  
3D printing is also known as additive manufacturing. It is defined as a process that is used 
for manufacturing 3 dimensional solid objects which are designed from digital files using suitable 
software.40, 41 Solid object or the end product obtained using an additive process means that it is 
fabricated by laying down layers successively on top of each other with the desired raw material 
till the final object has been created. 40,41 This technique allows us to make objects that are 
complex in shape and uses less amount of the raw material. These properties gives it the 
advantage of being fabricated easily and at very low cost. 40, 41,42  
The first 3D printer was developed in the 1980’s and it was based on the additive method 
with photo hardening thermoset polymer. Later 3D printers based on stereolithography (STL) 
were developed and these were equipped with curing of the photopolymers with UV light 
lasers.41 Recently, this technology has been classified into three as follows. Vat polymerization,   
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material extrusion and material jetting. Vat polymerization is further subdivided into 
Stereolithography (STL), Digital Light Processing (DLP) and Continuous Digital Light Processing 
(CDLP). There were classified depending on the method by which they are cured STL with laser, 
DLP with a projector DLP with LED and oxygen together. Fused deposition modelling was used 
not only to print functional prototypes but also concept models. FDM deals with production- 
grade thermoplastics. Lastly is Material jetting, which is classified depending upon the curing 
method and the polymer used. This subclass includes. Material jetting where curing is with UV 
light and the end product is plastic. Further depending on the size of the drops they are classified 
as nanoparticle jetting where curing is done with heat and the material used is metal. The last 
one is Drop on Demand which is milled to form the desired shape and the material used is 
wax.41,40  
 
 
Fig 1.2. 3DPrinted Devices designed in 123 Design software and printed using Formlabs, 
Form2 printer based on Stereolithography 
(A) The Immunoarray designed for the detection of protein cancer biomarkers 
(B) 3D printed pipette tip used to carry out “ELISA in a Tip” assay. 
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In our lab we used the Formlabs Form 2 printer (Fig 1.3. A) which is based on 
stereolithography and uses a clear resin for polymerization. Curing is done with the help of a UV 
laser. The instrument is equipped for making 3D printed microfluidic devices that are used for 
the automation and detection of proteins done via sandwich immunoassays. 40, 43, 44 
1.6. Goal and Summary of this Thesis 
The overall goal of research in our group has been to develop devices and use techniques 
for rapid, easy detection that would also be fully automated, highly sensitive, cost effective and 
involves multi-protein detection with moderate to high throughput with respect to the increasing 
need in clinical diagnostics of today. The devices used are developed using 3D printing technology 
and the methodology used was based on the generation of chemiluminescence (CL), which is 
obtained by applying a fixed voltage and then measured with a CCD (Charge Coupled Device) 
camera as a detector. The chemiluminiscense replaces the colorimetric detection of proteins   
 
Fig. 1.3. 3D Printing Technology. (A)Form2 printer by Formlabs. (B) Stereolithography 
technology on a Formlabs Form2 3D printer.  
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which is used in traditional ELISA thus modifying the ELISA kit assays which is considered the gold 
standard for protein detection and making it more suitable for POC testing.  
This thesis is organized into three chapters. Chapter 1 gives a general overview of the 
principles and a general background that is relevant to the work being described here. Chapter 2 
describes the first project dealing with the detection of multi-protein biomarkers that are specific 
to Prostate cancer. It also includes the use of automated pumps for simultaneous operation of 
four samples. The method involves utilizing Single walled carbon nanotube forests (SWCNT) as a 
substrate and Ru(BPy)32+ dye-doped silica nanoparticles acting as a label for ECL.14 In this system 
sandwich immunoassay is being utilized wherein the detection or the secondary antibody 
proteins are attached to the ECL label which in our case consists of the Ru (BPy) 32+- Silica 
nanoparticles which are immobilized to capture the primary or capture antibodies decorated on 
the SWCNT forest that are acid functionalized. The ECL signal thus obtained is directly associated 
with the concentration of the protein antigen. The ECL signal is produced in the presence of an 
electrolyte solution that contains a co-reactant, which in our case is tripropylamine (TPrA)24,45 
and is further measured using a CCD camera. Prostate Specific Antigen (PSA) and Prostate Specific 
Membrane Antigen (PSMA) are the two proteins specific to prostate cancer and thus acting as 
cancer biomarkers were chosen by us in this study.In Chapter 3 we describe pipette tip-based 
ELISA which is nothing but an ELISA done in a pipette tip. We used this concept as a next 
generation tool for the detection of cancer biomarker proteins with better sensitivity, shorter 
incubation times and lower volumes of sample and reagent requirements in comparison to the 
traditional or automated ELISA protein detection systems. This in turn serves to blend 
microfluidics to multi protein detection along with smartphone- based detection. We employed   
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the similar base of 3D printed devices that has been used previously in designing low cost pipette 
tips in order to carry out detection of proteins specific to any type of cancer inside the tips. The 
chemistry is exactly similar to the traditional ELISA but using lesser volume of samples and 
reagents. The sandwich immunoassay system is once again being utilized here in this system 
wherein the primary antibodies are immobilized on to the insides of the 3D printed tip followed 
by serially attaching the antigen and the secondary antibody and incubating them together. The 
detection of this system was done in two different ways A colorimetric pathway where a 
chromophore is used for color development, TMB in this study. This solution is further 
transferred to a 96 well plate as used in the usual ELISA assay and the absorbances are read using 
a Plate reader. The concentration of the protein is proportional to the color developed. Which 
means more the yellow color more is the concentration of the protein present in the sample. A 
smartphone-based app was used as an alternative method to read the results obtained giving it 
the advantage to be used in POC testing. The second pathway is using chemiluminescence, where 
luminol is used which generated a signal and utilized a CCD camera to capture an image which 
can be quantified with respect to the intensity of the signal. The signal intensity increases with 
the concentration increase. Vascular Epithelial Growth Factor (VEGF), Insulin- like Growth Factor 
(IGF)-1, Insulin like Growth Factor Binding Protein (IGFBP) 3 and Cluster of Differentiation (CD) 
14 are the biomarkers that were studied by us in this project.   
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Chapter 2 
Automated 4 sample Immunoassay of Cancer Biomarker Proteins using 3D Printed 
Microfluidics 
2.1. Abstract 
The purpose of Point of care (POC) testing is successfully being met with a combination 
of microfluidics and 3 D printing technology giving rise to the era of biosensors. POC testing 
protein diagnostics with full automation, low cost, high sensitivity, accuracy with rapid detection 
is of great importance and is in demand for future of biomolecular diagnostics. Herein we 
introduce a low cost, miniaturized, fully automated, 3D printed ECL immunoarray based device 
coupled with nanostructured pyrolytic graphite sheets decorated with microwells designed to 
detect 2 proteins specific to Prostate cancer simultaneously from complex blood serum samples 
with high sensitivity and selectivity. The time required for every assay was found to be just 18 
minutes with a cost of less than $1 requiring just 1 -2 microliters of sample volume. Automated 
programable syringe pump with a set program is employed to automate the process of delivering 
the sample and the reagents respectively to the detection chamber along with the desired wait 
time for incubation which completes the sandwich immunoassay. ECL technique is used for 
detection being a technique that is rapid and is ideal for detection of proteins. The sandwich 
immunoassay is completed by the sequence of Single walled carbon nanotube (SWCNT) forests 
which are the nanostructured materials used in our research that are immobilized on the PG 
chips which are then decorated with primary antibodies (Ab1) (capture antibodies), antigen and 
then the final layer of Ru (BPy)32+- silica nanoparticles that have been coated with secondary 
antibodies (Ab2) which are the detection antibodies. Prostate Specific Antigen (PSA) and Prostate  
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Specific membrane antigen (PSMA) were simultaneously measured from human serum on the 
immunoarray with detection limits 150 fg mL-1 for PSA and 230 fg mL-1 for PSMA, their dynamic 
range goes to 5 ng mL-1. Single protein ELISA was used to validate the immunoarray showing good 
correlation in measuring these proteins from human serum. These in collaboration with 3D 
printed platforms used to fabricate the devices required for the automation purpose could be 
easily done configuring to CAD files which are available on the lab group website and can be 
applied to various other applications and also can be modified as per requirements.  
2.2. Introduction 
The gold standard used for protein detection so far has been ELISA. However, it is 
associated with terms like labor intensive, time consuming, higher volumes of sample and 
reagents and expensive.46, 47 A very important feature that ELISA is that it has been associated 
with single protein detection. With point of care detection, we are mainly looking at detection of 
multiple proteins and with POC protein testing simultaneous detection of a panel of proteins is 
gaining importance. With this we can imagine the time being multiplied for the detection of multi 
protein detection systems which is a requirement for the efficient detection systems employed 
for point of care testing. Thus, the need for fast, fully automated, sensitive and low cost 
immunoarray biosensors for the analysis of multi proteins for diagnostic purposes. In this 
technical note we describe exactly that. A microfluidic 3D printed device that was designed using 
CAD files that are available on our lab website and then 3D printed. These are set up with a 
detection PG chip and is run with the help of auto- programable pumps. This entire set up can be 
used for the detection of 2 or more proteins simultaneously. Also 4 samples can be run at the 
same time. Finally, the detection is done using low light sensitive CCD camera.48,49, 50,51, 52   
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With 3D printing technology low cost of fabrication with the advantage of being able to design 
any object with little knowledge of the software has become possible. It thus plays a very 
significant role in the all growing fields of industry. Stereolithography (SLA) a type of 3D printing 
that is based on laser assisted polymerization is used in order to fabricate clear plastic objects 
and devices.53, 54, 55 These properties make the technology most suitable for use in biosensor 
devices. Especially for protein detection using ECL technique.56 
 In our lab we have developed 3D printed fully automated microfluidic devices with 16 
microwells that attach the capture antibodies through carboxylate functionalized SWCNT’s and 
Ru (Bpy)32+- Silica nanoparticles that are coated with detection antibodies for the detection of 
proteins using ECL technique.56 The array utilizes an Arduino microcontroller system that has 
been developed for the auto switch on and switch off of the pumps according to the preset 
program developed in our lab for delivering the reagents and the samples automatically thus 
creating a fully automated system with CCD camera for detection purposes.56  In our current work 
we have defined a simplified version of our 16 microwell array that is used along with a readily 
available syringe pump in order to be able to run 4 samples simultaneously and detecting 2 
markers together. The dimensions of the 3D printed microfluidic array are 3 x 4 x 0.3 cm, these 
dimensions offer low reagent and sample usage with the detection of 2 prostate cancer 
biomarker proteins in four 100 μL serum samples in just 18 mins for a cost that is estimated to 
be less than $ 1 in reagents.   
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Fig 2.1: Entire set up. To the left is the Syringe Programmable Pump equipped to run 4 
immunoarrays set up on a 3D printed microfluidic device. To the right is an enlarged model of 
the 3D printed microfluidic device used and attached to a pyrolytic graphite (PG) chip that 
contains 4 microwells for the detection.57 
 
2.3. Experimental  
2.3.1. Chemicals and Materials 
Pyrolytic graphite sheets (PGS) were from Panasonic Industrial Devices and 
Solutions (EYGS121807), clear resin (GCPL02) from Formlabs (Somerville, MA). Pure prostate 
specific antigen (PSA, P3235) was purchased from Sigma-Aldrich and prostate specific 
membrane antigen (PSMA) was from Novus Biologicals, Anti-PSA capture (M0-T40081A) and 
detection antibodies (M0-T40081B), anti-PSMA capture (MO-T40086A) and detection 
antibodies (MOT40086B) were from Anogen. Single protein ELISA kit for PSA (RAB0331) from 
Sigma-Aldrich and PSMA ELISA kit (EL008782HU-96) was from Lifeome Biolabs/Cusabio. 
Human serum samples were obtained by George Washington University Hospital under 
ethical approval from Univ. of CT IRB. The Ru (Bpy)32+ Silica nanoparticles used for the label 
were synthesized by a method previously developed. The particles were characterized and  
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ideally have an average diameter of 115 ± 13 nm with the expected size to be between 90 to 
120nm. The Ru (Bpy)32+ silica nanoparticles were coated with layers of 
polydiallyldimethylammonium chloride (PDDA) and poly acrylic acid (PAA), and then these 
were covalently linked to detection antibodies (Ab2) using 1-(3-(dimethylamino) propyl)-3- 
ethylcarbodiimidehydrochloride (EDC) and N-hydroxysulfosuccinimide (NHSS) as described 
previously.58 Ru (Bpy)32+ - silica detection nanoparticles were decorated with two different 
types of antibodies, PSA (PSA-Ab2) and PSMA (PSMA-Ab2). Optimized Ab2 concentrations of 8 
µg mL-1 for both anti-PSA and anti-PSMA were used to make the RuBPY-SiNP-Ab2 conjugate, 
and the Ab2/ Ru (Bpy)32+ – SiNP ratio was measured at 38:1 using the BCA total protein assay. 
All immunoreagents were dissolved in pH 7.2 phosphate buffered saline (PBS). Co-reactant 
solution for ECL was 500 mM tripropylamine (TrPA) with 0.05% Tween-20 (T20) and 0.05% 
Triton-X in 0.2 M PBS. Specific capture antibodies were coated onto SWCNT which were 
already decorated on the detection microwells of the PG chip for 2.5 hours at room 
temperature followed by adding 2% BSA as a blocking agent for 1 hour to minimize 
nonspecific binding and stored at 4°C until use.  
 
2.3.2. Instrumentation  
We have in the past designed 3D printed devices in our group to make 
immunosensors. The design of these devices has been altered and modified over the years 
according to the requirement of the project and the product being analyzed. Since we in this 
project are dealing with 2 proteins and more in other projects up to 4 proteins, the device 
needs to modified for the size of the detection chamber and the volume capacity of the other   
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reagent chambers. The printing for the 3D printed array was done with the help of Form 1 + 
SLA printer by Formlabs (Somerville, MA). The entire sensor was equipped with the three - 
electrode system which is the working Pyrolytic graphite sheet (PGS) with microwells loaded 
with Ab1 attached through SWCNTs, the reference Ag/AgCl electrode and the platinum wire 
counter electrode. This system is used to give the ECL signal which is obtained when a fixed 
potential of 1.0 V is applied by a CHI 660 electrochemical workstation to the 3- electrode 
system in the presence of the co- reactant 500 mM TrPA. 
 
2.3.3. Fabrication of the 3D printed device 
2.3.3.1. Abstract 
Clear plastic devices incorporating microfluidics with ports available for inserting 
electrodes that can be used in electrochemiluminescence (ECL) measurements were 
prepared using low cost desktop three- dimensional (3D) printer that is based on the 
concept of stereolithography (SLA). The electrode included 0.4 mm platinum wise as the 
counter electrode and 0.6mm Ag/ AgCl wire as the reference electrode. The 3 - electrode 
was completed using the PG chip array which acts as the working electrode. This device also 
includes an inlet port for the plastic syringe which is attached to the auto programmable 
pump equipped as the pumping device for delivering the reagents in the system to the 
detection chamber of the device. A bioimaging system which includes a dark box equipped 
with a CCD camera along with the device is being used to measure ECL signal that is 
generated at the electrodes with solutions containing tris (2’,2’- bipyridyl)   
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dichlororuthenium (II) hexahydrate ([Ru(bpy)]32+) and with 100 mM of tri propylamine 
(TrPA) as the co- reactant.  
 
2.3.3.2. Introduction 
While 3D printing first evolved in the 1980s, it was limited to use because of its 
very high cost, limited availability of materials and the printers itself. With the growth of 
research and technology there came various changes and improvements in the world of 3D 
printing. The cost of the printers, their availability and materials improved. The technology 
was most widely accepted because of its ease of use and its very fast ability to go from 
design to final object. Today 3D printing had made its place for the use of making 3D printed 
devices that can be used as biosensors because it can deal with very small volumes thus 
supporting microfluidics. Hence, they are widely being used currently for the analysis of 
biomolecules. In our lab we have successfully adapted the most upcoming 3D printing 
technology to make immunosensor devices that can be used for the detection of protein 
biomarkers. 
 
2.3.3.3. Chemicals and Materials 
Clear resin purchased form Formlabs (Somerville MA) (this is nothing but poly 
acrylate polymer resin) (GCPL02), Isopropanol, clear acrylic spray KrylonTM. Platinum wire 
and Ag/ AgCl for electrodes. 
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2.3.3.4. Experimental Section – Software and design  
The microfluidic device was designed using 123 Design software (Autodesk, San 
Rafael, CA). The software was downloaded online free of cost and used. Other software’s 
that are available and could be used include Fusion 360. The microfluidic array has the 
dimension of 3 X 4 X 0.3 cm (L x W x H) (Fig 2.2 A) and is made up of 8 channels that run 
parallel to each other and are connected by loops in order to flow reagents from one 
channel to another. In addition to the 8 reagent and sample chambers the device has the 
detection chamber. The detection chamber is kept open at the bottom unlike the other 
chambers (Fig. 2.2 A&B). This is done for the attachment of the PG chip array decorated 
with Ab1 required for the immunoassay. Each of the reagent chambers are separated by air- 
filled chambers that help preventing the reagents from mixing. The dimensions of each of 
the sample and reagent chambers are (L x W x H) 18 x 2.5 x 0.5 mm, the dimension of the 
detection chamber is (L x W x H) 12 x 2.8 x 0.5 mm. Fig 2.2 Chambers 1 and 2 are assigned 
for PBS – TWEEN-20 buffer (PBS buffer with 0.05% TWEEN -20, pH- 7.4), Chamber 3 is for 
air gap preventing the mixing of reagents. Chamber 4 has been designated for Ru (Bpy)32+ - 
SiNP- Ab2 ECL label, followed by chamber 5 for air gap, chamber 6 has PBS buffer (pH -7.4) 
acting as wash buffer. Chamber 7 is an air gap, chamber 8 is the sample chamber which 
finally leads into the detection chamber, the PGS array is attached at the detection 
chamber. The volume capacity of all the chambers is about 20 μL ± 2 μL. All of the reagents 
and the sample are added through 0.8 mm holes that are designed and made on the 
chambers. They are referred to as injection ports. Other hole openings also have been 
provided and are called as vent holes facilitating reproducible filling of the chambers. As   
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the chambers have confined space and the volumes introduced in these chambers are very 
small they tend to replace the air inside the chamber as soon as the reagent/ sample is 
introduced. This helps in precision loading which is an important factor for the assay for 
better control over automated delivery of the reagents and the samples to the detection 
chamber. Micropipettes were used for addition of the reagents and sample. The detection 
chamber is equipped to hold 0.4 mm platinum wire as the counter electrode and 0.6mm 
Ag/ AgCl wire as the reference electrode. They are placed such that they run parallel to each 
other, with the PG chip attached acting as the working electrode the set up for the 
3electrode system is complete. In addition, the device has an inlet port for the attachment 
of the plastic syringe with the connection made through flexible tubing filled with 100 μL 
of 500mM TrPA solution drawn into it. With this the setup is complete and the device is 
ready to use. 
 
2.3.3.5. Fabrication and Printing 
Once the design is done it is converted to a printable format which is compatible 
with the 3D printer mentioned using splicing software preform as shown in Fig 2.2. With 
the help of the preform software the design is first rightly oriented and then supports are 
generated which are necessary for the printing process as they hold the device being 
printed to the stage of the instrument. An important point here is that depending on the 
size of a single device the desired number of replicates can be printed at the same time by 
just rightly orienting them using the same preform software. Once everything is done the 
devices are ready to be printed. On completion the devices need to be washed immediately   
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and sonicated with isopropanol for at least 15-20 minutes in order to get rid of the excess 
resin that might be uncured and in the channels. They are then air dried and sprayed with 
clear acrylic spray KrylonTM. This makes the device see through in order to monitor the flow 
of the sample and reagents. The time required for printing one device is about 1h 24 mins. 
The time changes depending upon the number of devices being printed. 
 
Fig. 2.2. Representations of the 3D printed device. (A) A Model of the array labeled with 
reagent chambers and connected to 4 microwell pyrolytic graphite (PG) detection chip. A 
Programmable pump is connected to the array via the inlet port at the syringe end to deliver 
the contents of each chamber in a sequence. (B) A Photograph of the 3D printed microfluidic 
array with its chambers filled with colored dyes for visualization. 57 
 
2.3.4. Fabrication of the Pyrolytic Graphite Chip Electrode 
The PG detection chips were fabricated using paper thin, flexible, conductive, 
Pyrolytic Graphite sheets (PGS).59 The PGS was first placed on a support made of plastic, and 
then cut into chips of the desired size such that it can fit 4 microwells. The microwells are first 
patterned or designed in Inkscape designs software. Each of the 4 microwells is 1mm in  
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diameter (~10 nm deep) with 2 microwells with 2 assigned for PSA and 2 for PSMA. The 
patterned microwells are then printed on glossy paper (Avery TM 5263) with the help of an HP 
laser jet printer. The microwells thus printed are formed by the use of hydrophobic toner 
from the printer which gives it boundaries that helps in implementing and building of SWCNT 
forests and antibodies within the boundaries as the toner is hydrophobic.47, 44 Then finally 
these microwells are transferred on to the PGS chips mounted onto the plastic support. This 
is done by a heat press for 90s at 275 ºC  (Fig. 2.5 A).59 The Scanning electron micrographs of 
the sheets with the microwells on it have been shown in Fig. 2.5 B. The tapping mode Atomic 
force microscopy (AFM) results showed that the unmodified or the original sheets were 
smoother with a surface roughness of 35 nm Fig 2.5 C & D. On the other hand, the surface 
roughness of the modified PG sheets that is those with the SWCNT forests was seen to be 47 
nm, Fig 2.5 E. The microwells are first set up to attach the SWCNT forests, for which they are 
coated with layers of Nafion and FeCl3 followed by the SWCNT forests serially. The arrays are 
incubated with each of the reagents for 10 minutes and washed in between with water or 
methanol. The SWCNT forests and the arrays together are incubated for 4 hours at room 
temperature. At the end of the incubation time the SWCNT forests are functionalized by 
carboxyl groups at their ends with 400 mM EDC + 100 mM NHSS. The functionalization helps 
the capture of antibodies (Ab1) by the chemistry of amidization which is also called as zero 
crosslinking.60 AFM results of the PGS  after attaching the antibodies showed to decrease the 
surface roughness to 38 nm. This is accounted for due to the globular nature of antibodies. 
These patterned PG sheet arrays with microwells decorated with SWCNT forests and capture  
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 antibodies (Ab1) all together attach to the detection chamber of the 3D printed array using 
double sided adhesive (Aleene’s® Tacky Double- Stick Sheets TM). 
 
2.3.5. Synthesis of Single walled Carbon Nanotube Forests 
Carbon nanotubes were discovered sometime in the 1991 by Iijima.61 Carbon 
nanotubes have enhanced properties like high thermal and chemical stability, high tensile 
strength and excellent conductivity. These are the properties of the carbon nanotubes that 
have made them of great interest for sensor applications that deal with electrochemistry62 
and ECL detection.62 These carbon nanotubes have additional attractive features of providing 
a large conductive area and functionalized surface area for the attachment of capture 
antibodies. We used functionalized SWCNT forests on the surface of PG chip arrays. This gave 
a platform for the detection of cancer biomarker proteins in more complex samples like blood 
serum.63, 64, 36 We have successfully synthesized ~ 30 nm long carboxylated SWCNT forests, 
which have the ability to stand upright in bundles on a thin Nafion – iron oxide layer coated 
on the microwells of the pyrolytic graphite array surface. The carboxylic groups that are 
formed at the ends help in the capture of antibodies with the help of EDC-NHSS amidization 
reaction. The carboxylic groups at the ends of the SWCNTs are obtained by acid treatment - 
HNO3 and H2SO4 of the SWCNT.36 (Scheme 2.1) They are then uniformly dispersed and stored 
in DMF, and when placed on the PG chip surface they tend to align themselves upright all 
parallel to each other because of the negatively charged polyelectrolyte Nafion and Fe(OH)x 
that are already present on the surface of the chip. The SWCNTs dispersion just causes the 
Fe3+ layers immobilized on the surface is transformed in to its basic hydroxide form. This is   
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nothing but an acid base neutralization which is responsible for this assembly. The SWCNT 
forests increase the surface area for the attachment of a greater number of antibodies that 
contributes to greater sensitivity of the sensor. In the past SWCNT forests have been used to 
build ultrasensitive amperometric immunosensors that detected PSA in blood serum and 
tissue lysates using multiple enzyme labels. Here the current is proportional to the 
concentration of the protein being detected. These were then replaced by [Ru (bpy)32+] doped 
nanoparticles that provided amplification and that the ECL signal is proportional to the 
concentration of protein.60,58  
 
Scheme 2.1 Schematic Representation of s- SWCNTs Self-Assembly Process.60 
 
2.3.6. Synthesis and Characterization of Ru(bpy)32+   
Dye doped silica nanoparticles show promise in being used as label for ultrasensitive 
immunoassays that use ECL for detection. We use Ru (Bpy) doped silica nanoparticles for our  
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method of detection of proteins. In this Ru (BPy) is trapped inside the nanoparticles which is 
done by reverse water in oil (W/O) microemulsion method of synthesis. In this method the 
water in oil emulsion was prepared first by mixing 1.77 mL of Triton X- 100, 7.5 mL of 
cyclohexane 1.8 mL of n – hexanol. This mixture is allowed to stir at a suitable speed on a 
magnetic stirrer for about 15 minutes. After 15 mins 340 μL  of water with the luminophore 
Tris (2’,2’- bupyridyl) dichlororuthenium (II) hexahyderate (0.04 M) RuBpy is added to it 
dropwise with optimum stirring as this step will determine the size of the particles being 
formed at the end of the synthesis. The mixture is allowed to stir for 30 mins. This is followed 
by the addition of 100 μL TEOS (tetra ethyl ortho silicate) and 60 μL Ammonium hydroxide 
28 -30%. The reaction is allowed to stir for 24 hours in the dark after which the particles are 
precipitated in acetone and the washed with water and ethanol several times to remove 
excess surfactant molecules. It has to be noted that the entire reaction should be carried out 
in the dark or with minimum exposure to light. A single nanoparticle can encapsulate 
thousands of RuBPy molecules to have a large signal amplification which is an advantage to 
giving greater sensitivity. The Ru (BPy)32+-SiNP were then characterized for several 
parameters. The average size diameter of the particles was found to be 115 ± 13 nm.  
 
Characterization of Ru (BPy)32+- SiNP- Ab2 bioconjugate 
2.3.6.1. Transmission Electron Microscopy (TEM)- Size of the synthesized particles 
20 mg of the Ru (Bpy)32+-SiNP that were prepared were dispersed in pure water 
making a final concentration 20 mg ml-1. A drop of this dispersed liquid is placed on a silica 
wafer followed by vacuum drying for a day to prepare the sample for TEM characterization.  
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The TEM characterization is done for the Ru (Bpy)32+-SiNP only without modification to 
attach the antibodies. About 100 nanoparticles were analyzed for this purpose and the 
average size distribution estimated from the analysis was 115 ± 13 nm in diameter. (Fig.2.3) 
 
Fig 2.3 Size Characterization of the Ru doped SiNP’s (A) TEM image of Ru (BPy)32+- SiNP’s on a 
500 nm scale bar (B) Size distribution of Ru (Bpy)32+- SiNP’s with an average diameter of 115 ± 
13 nm. 
 
2.3.7. Preparation of the ECL Detection Label by coating Ru(bpy)32+ Silica Nanoparticles with 
Ab2  
The Ru(bpy)32+ Silica Nanoparticles (115 ± 13 nm average diameter, pore size 4nm) 
were used for making the ECL labels. Ru (BPy)32+ Silica Nanoparticles (2 mg mL-1) were 
prepared in water (2 mg in 1 mL of water). The solution is well sonicated and centrifuged at 
10,000 rpm for 10 mins. The supernatant is then discarded and the particles are incubated 
with a 170 μL of 2 mg mL-1 aqueous PDDA adding 830 μL of water to it. for 15 mins and 
then centrifuged at 9,000 rpm for 10 mins. The supernatant is once again discarded and the   
31 
particles are washed 3 times with water centrifuging at 9,000 rpm for 10 mins. The particles 
were then resuspended in 170 μL pf 1mg mL-1 PAA solution and incubated for 15 mins 
followed by centrifugation and washing steps as before. The PDDA thin layer (~ 0.5 nm) is 
used to avoid blocking the pores of the particles and PAA layer was added was added so as 
to place the carboxylic acid groups on the outer side of the particles in order to link the Ab2 
through EDC – NHSS amidization. After addition of the PAA and serially washing the particles 
with water they are resuspended in 1 mL freshly prepared 400 mM EDC and 100 mM NHSS 
in PBS buffer at room temperature and incubated for 10 mins and then centrifuged and 
washed three times with water. Finally, the PAA/PDDA/RuBPY- SiNP’s are resuspended and 
incubated in with the antibodies of the desired concentration (8 mg mL-1 for both PSA and 
PSMA) for 8 hours at room temperature with constant shaking condition. After the 
completion of 8 hours the reaction mixture is centrifuged at 4 ºC for 10 mins at 13,000 rpm. 
It is then washed 3 times with PBS buffer solution (pH 7.0), this helps remove the free PSA 
or PSMA- Ab2 and then finally stored in 1 mL of 2% BSA in PBS buffer + 0.05% Tween- 20. 
This finally gives us the uniformly dispersed ECL label that is stable for about 4 weeks when 
stored in the refrigerator at 4 ºC. 58 
2.3.7.1. Estimating the number of RuBPY in the Silica nanoparticles 
The number of RuBPY in the silica nanoparticles can be obtained from the 
relation between viscosity of a dilute solution of the nanoparticles and the volume fraction 
of the suspended nanoparticles (Φ) and is given by equation 1, 
h
h0
= 1 + 2.5(𝜙)  ................................................................................................... (1) 
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Viscosity of the suspension was obtained to be 1.0078 and that of the solution 
without the particles was 1. Substituting the values in the equation above gave the value 
of Φ to be 0.00031. The number of particles is given by (N) and is obtained using the 
formula in equation 2  
N =
ϕ
4
3
πr3
   ........................................................................................................... (2) 
The value of ‘r’ is obtained from the value of the diameter of the nanoparticles 
obtained using transmission electron microscopy. In our case the value was found to be 
115± 13 nm. Substituting this value into the second equation the number of particles was 
calculated to be 3.4 x 1011 per mL of the solution. 58 
 
2.3.7.2. Determination of Ab2/ Ru (BPy)32+ - SiNP Ratio 
The molar concentrations of secondary anti-PSA antibody or anti-PSMA 
antibody and antibody/ [Ru (BPy)32+] in the ECL bioconjugate or the ECL label can be 
obtained by fluorescence detection experiments. Antibodies contain tryptophan, which 
excites at 280 nm specifically. A calibration curve is obtained for known concentrations of 
Ab2 Fig 2.4. The curve thus obtained is seen to be linear and the unknown concentration 
of Ab2 from the ELC label or the bioconjugate which is PSA-Ab2 or PSMA- Ab2 in 2% BSA, 
PBS Tween-20 at pH 7.2 and the control which does not contain antibodies is nothing but 
2 % BSA, PBS Tween-20; at pH 7.2 can be calculated. The concentration of Ab2 thus 
obtained was calculated to be 3.5 μg/ mL. From this the number of Ab2 on the 
bioconjugate was calculated to be 1.31 x 1013. Thus, the ratio of Ab2 to RuBPY silica 
nanoparticles was calculated to be 38:1.57  
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Fig 2.4 Calibration Plots for calculating Ab2/ Ru(bpy)32+ - SiNP Ratio by plotting concentration 
of the secondary antibody and [[Ru-(bpy)3]2+] nanoparticles coated with antibodies against 
fluorescence intensity (A) at 280 nm wavelength with [ secondary antibody] range: 3.125 – 75 
μg/mL. (B)Plot at 547 nm wavelength with [[Ru-(bpy)3]2+] range: 0.5 – 2 mg/mL57 
  
2.3.8. Fabrication of the Immunosensor/ Immunosensor Protocol 
For running the final part of the assay all the parts should be assembled together. 
Which included the 3D printed array device with all the chambers filled with the respective 
reagents, attaching the Ab1 capture antibody loaded on the PG chip microwell. The vent holes 
of the device are sealed with one- sided transparent tape. Flexible tubing was attached to a 
BD plastic syringe 4.8 mm, 1 mL capacity. The open end of the tubing was inserted into the 
inlet port provided on the 3D printed array. The tubing is filled with 100 μL of 500 mM 
tripropylamine (TrPA) in 0.2 M phosphate buffer + 0.05% Tween- 20 and 0.05% Triton X- 100 
with pH-7.5. TrPA acts as the co- reactant for ECL generation. This completed the set up and 
fitting the syringe into the Chemyx Fusion Touch programmable syringe pump which has a 
three-step program that is set up to control the flow of the reagents which includes 
incubation times. The pump is set to 90 μL min-1, Step 1 settings involve volume of 27 μL, 
with the pressure build up time and dead volume time included in it. This is followed by a  
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delay of 8 minutes as the sample needs to be incubated on the PG chip array. Step 2, settings 
involves the pump delivering 130 μL  of wash buffer also flushing out the sample and then 
delivering the ECL label of Ab2 – RuBPY- SiNP which is again set up to incubate for 7 minutes. 
Step 3, the pump cycle is set up to 600 μL to flow the wash reagents and remove the 
unwanted detection NPs, and in turn fill the detection chamber with the co-reactant TrPA. 
The immunoarray is then placed in a dark box fitted with a CCD camera, Syngene G: box F3. 
The camera is set to get the best possible signals with the help of a software Genesnap 
Tools®. Making the respective connections to the electrodes a potential of 1.0 V is applied 
Vs Ag/ AgCl by a CH Instrument Electrochemical Analyzer for 180s. The mechanism of ECL 
generation is predicted to be like, TrPA gets oxidized to TrPA•+ when the potential is passed, 
TrPA•+ then deprotonates forming TrPA• and it is this that drives the catalytic redox reaction 
that involves [Ru(BPy)]2+/3+ this in turn gives the electronically excited state [Ru(BPy)]2+* 
which when comes back to the ground state emitting light called chemiluminiscense.58 The 
ECL images thus obtained were processed using the software to obtain the respective 
standard and sample ECL intensities.65  
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Fig.2.5. Graphical representation of the immunoassay 
 
Scheme 2.2 Probable ECL Pathway.on applying potential of 1 V Vs an Ag/ AgCl electrodeis from 
on-board potentiostat. The TrPA co-reactant gets oxidized reacting with RuBPY from the ECL 
label. The direct oxidation occuring on the surface of the PGS chip electrode forms TrPA cation 
radical which in turn forms TrPA radical and H+. TrPA radical then reacts with [[Ru-(bpy)3]2+] to 
generate [[Ru-(bpy)3] +]. This [[Ru-(bpy)3] +] reacts with TrPA cation radical it produces photo 
excited [[Ru-(bpy)3]2+] * which readily generated ECL signal at 610 nm. 
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2.4. Results and Discussion 
2.4.1. Characterization of the Pyrolytic graphite array surface after modification 
AFM is used for studying the surface characteristics of the PGS arrays at different 
stages in order to study the changes occurring with the addition of reagents. 
 
2.4.2. Electrochemiluminescence Immunoassay Development 
2.4.2.1. Calibration curves for ECL Single Protein Detection 
Calibration: Prostate Specific Antigen has been associated as a standard 
protein biomarker for screening prostate cancer.51 Benign prostate diseases are also 
known to increase the levels of PSA and this can lead to false positive results. Prostate 
specific membrane antigen (PSMA) is known to be overexpressed in early metastatic, and 
hormone refractory prostate cancers.66, 67 PSMA is thus considered a potential protein   
 
Fig 2.6 (A) Data obtained by Dr.Islam Mosa of the disposable pyrolytic graphite sheet with 
microwells formed by hydrophobic toner from a printer. Inset is the sandwich immunoassay 
as on the single wall carbon nanotube forest (SWCNT). (B) SEM image showing hydrophobic 
boundary that is formed giving the desired wells (C) The inside of a microwell on the PGS. (D-
F) Tapping mode AFM images of unmodified PGS, PGS+SWCNT forest in a microwell, and PGS+ 
SWCNT+ Ab1 immobilized in a microwell, respectively.57 
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biomarker in serum and can be used along with PSA as a 2-biomarker panel for prostate 
cancer diagnosis. Beginning with the analysis of a single protein where all the 4 microwells 
on the PG chip detection array are coated with either PSA or PSMA specific capture 
antibodies and the ECL detection label has either the PSA or PSMA detection antibodies. 
In order to test the reproducibility of the system the relative ECL responses captured from 
the 3D printed immunoarray with three trials in undiluted calf serum that has zero-PSMA 
concentration which acts as the control and 1 pg mL-1 PSMA. The results were observed 
to show an average relative standard deviation (RSD) of 8% well- to – well (n=4) and 6% 
array – to – array (n=3). The 3D printed arrays were calibrated with PSA and PSMA 
individually and it was seen that the ECL signal increases as the concentration of the 
protein biomarker increases. The ECL signal intensities from the CCD camera were 
accumulated for 180s. The analyte concentrations are obtained by subtracting the signal 
of the controls that is zero concentration of protein which were then plotted against the 
concentration. 
After analyzing single proteins, PSA and PSMA were then analyzed 
simultaneously by using a mixture of concentrations of the standards of both PSA and 
PSMA prepared in undiluted calf serum.  The first 2 microwells were assigned for anti- 
PSMA capture antibodies and the next 2 microwells were assigned for anti- PSA capture 
antibodies (Fig 2.6 A). With all of this the ECL label prepared also has both anti- PSMA and 
anti PSA antibodies coated on the Ru(bpy)32+ - SiNP’s. With the help of a programable 
pump that has a preset program the reagents are step wise flown into the detection 
chamber. The sample is first to go and is incubated for 8 mins, followed by wash 20 mM   
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PBS buffer pH- 7.4, followed by the Ru(bpy)32+ - SiNP’s- Ab2 ECL label delivered and 
incubated for 7 min, followed by 2 washings with PBS buffer in tween 20, pH- 7.4. Finally, 
TrPA co- reactant is incubated in the detection chamber and the ECL signal is measured. 
The relative ECL intensities plotted against the concentrations of the standards give us 2 
calibration curves. (Fig. 2.7.) 
 
Fig. 2.7. Calibration data form the simultaneous detection of PSMA and PSA biomarkers in 
undiluted calf serum along with the ECL responses integrated over 180 s at 1.0 V vs Ag/AgCl. 
(A) Shows the recolorized images captured from a CCD camera of 5 arrays of different 
concentrations showing an increase in ECL response with increase in concentration. Influence 
of concentrations on relative ECL response for (B) PSMA and (C) PSA, the error bars show 
standard deviation for n=4.57 
 
In Fig 2.7 A we see the re-colorized images from the CCD camera showing ECL 
responses of the mixture on the same PG array detection chip in calf serum. Calf serum 
proves to be a good surrogate for the immunoassay calibration because the final samples 
are in human serum. Fig 2.7 B & C show the actual calibration curves and it is seen that 
the plots show curvature in the upward direction. These calibration curves are still reliable 
for the detection of protein in the dynamic ranges of 250 fg mL -1 to 5 ng mL -1 for both   
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proteins. The detection limits were 150 fg mL-1 for PSA and 230 fg mL-1 for PSMA, given 
by 3 x SD above 0 pg mL-1 protein control. 
 
2.4.2.2. Receiver Operating Characteristic Curves for 38 human serum samples 
Analysis of Patient Samples: 32 samples from cancer patients and 6 control 
samples from cancer free patients were analyzed. In addition to the above patient sample 
analysis, 9 samples were selected across the dynamic range and analyzed by single 
protein PSA and PSMA ELISA kits to establish a correlation between the detection of 
protein cancer biomarkers by gold standard ELISA and our immunoarrays. The samples 
were diluted for this purpose 100 to 500-fold in calf serum prior to analysis, this is to bring 
down the ECL signal response to be within the dynamic range.  
 
Fig. 2.8. Box-and-whisker plots summarizing the patient sample results obtained from the 
assay to show data point distribution for cancer-free and prostate cancer serum samples for 
(A) PSA and (B) PSMA. The plots present lower, upper quartile, and median values along with 
minimum and maximum ranges. 
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Table 2.1 Conentration of PSA and PSMA that are obtained from the multiplexed ECL detection 
assay for prostate cancer and prostate cancer negative patient samples 
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The concentration of the proteins in patient samples done by the assay are found to be 
as given in table 2.1.  
The plots seen in Fig. 2.8. show a visual comparison of the protein concentrations that 
were found in patient samples by the immunoassay. The central boxes seen represent values that 
lie in lower to the upper quartile which is 25 to 75 percentiles. The horizontal lines seen in each 
box represents the median, while the vertical lines and box ends represent the minimum to 
maximum concentrations in the samples. The median values are seen to be significantly larger in 
the serum of a cancer patient for both PSA and PSMA. Most of the values segregate into sub- 
groups that are for cancer free and cancer patients. All of the results obtained from the analysis 
suggest that the 2 proteins PSA and PSMA together differentiate well between the serum of 
patients with prostate cancer and cancer free patients. 
 
Fig. 2.9. Receiver operating characteristic curves (ROC) plotted for the 38 human serum 
samples analyzed by the assay. (A) Red line indicates PSMA and Blue line indicates for PSA 
showing AUC to be 0.89 for PSA, 100 % specificity and 78.1% sensitivity and for PSMA, AUC 
was calculated to be 0.92, 100 % specificity and 78.1 % sensitivity. (B) Normalized PSA and 
PSMA results suggest 0.95 AUC, 100 % specificity and 81.3 % sensitivity 
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2.4.2.3. Comparison of ECL Vs ELISA 
The accuracy of the assays was validated by comparing sample analysis to 
standard single protein analysis done by ELISA’s. Comparison studies done between ELISA 
and the immunoarrays yielded very good results as shown in Fig. 2.10.  
 
Fig. 2.10. Data collected by Mohammed Saharafeldin for the comparison of ECL assay vs. ELISA 
for 9 human patient serum samples. The Bar graphs show ECL and ELISA values for (A) PSA and 
(B) PSMA. The Linear correlation plots are given in (C) PSA and (D) PSMA. With Error bars and 
standard deviations with n=4 for ECL and n=3 for ELISA. 
 
2.5. Discussion 
The results obtained support the claim that a low cost, 3D printed immunoarray provides 
excellent characteristics for the detection of multi samples by automated assays having low 
abundance proteins in complex samples of blood serum, measuring the levels of PSA and PSMA 
in the pg mL-1 range in human serum containing thousands of other proteins out of which many   
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are in the mg- mL-1 range.68 With the LOD’s of 150 fg mL-1 for PSA and 230 fg mL-1 for PSMA it can 
be said that the 3D printed microfluidic device is capable of detecting ultralow levels of 2 proteins 
in blood serum simultaneously in about 20 min assay time utilizing just 1-2 μL  of sample volume. 
The programmable pump used allows the sequential pumping of the sample and reagents to the 
detection sensor and also allows the precise control of the delivery facilitating incubation and 
washing to be fully automated without user participation. The total cost of the assay was 
estimated to be $0.75 which makes the use of this technology together for applications in 
laboratories and for POC testing including low resource settings.  
The dynamic ranges for both the proteins obtained from the respective calibration curves 
ranged from 250 fg mL-1 to 5 ng mL-1. These match the clinical ranges for the selected proteins 
with a 100- 500- fold dilution. The Relative Standard deviation ranged from 2 to 11% overall. 
Good repeatability and reproducibility were seen from assay to assay (<±8%) with control and 
1pg mL-1 PSMA. The accuracy of the assay has been confirmed by the comparison of the results 
of the ECL immunoarray to the gold standard ELISA.  
 The use of 3D printing technology enabled a compact design consisting of different 
reagent chambers and a detection channel within the same piece of device. The parallel 
alignment of the sample and reagent chambers to the detection chamber with optimized 
distance between each of them helped in the rapid completion of the assay helping with full 
automation of the system.  
The PGS were used in place of the PG block or the screen- printed arrays previously used 
as they were low cost, flexible and thus easy to handle, cut and use, disposable, highly conductive   
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and could also withstand organic solvents. The cost of one PGS 7in X 5in with a thickness of 
0.0028in is $6. Approximately 75 sensor chips can be made out of one PGS, in turn making a 
single chip would cost just 8 cents. The cost of printing including all the materials is $0.40. Making 
the overall cost $0.75. The arrays can be disposed after use.   
 
2.6. Conclusion 
Thus, we can say that we successfully demonstrated the use of inexpensive desktop 
stereolithographic 3D printer to develop a compact, optically clear microfluidic array that is most 
suitable for ECL detection. The device is low cost and portable and capable of sensitive and 
selective detection of 2 protein biomarkers from human serum samples. Programable pumps 
gave the dimension of automation for the analysis of 4 samples simultaneously. The assay is low 
cost and rapid with low detection limits and dynamic ranges that gives additional advantage for 
them to be used for clinical analysis.   
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Chapter 3 
Equipment free, smartphone interfaced 3D Printed “ELISA in a Tip” for Multiplexed Protein 
Detection 
3.1. Abstract 
ELISA has been the gold standard for all plate- based protein detection systems for 
decades now, but there are available and frequently used fully automated devices that use 
complex engineering and robotics having fluid control but have a very high cost and are bulky in 
size devices. 3D printing technology has found use in varied fields in recent times. Here we 
combine 3D printing technology along with microfluidics again to make pipette tips to carry out 
the widely recognized ELISA aiming to carry out protein detection efficiently. This Tip- based 
ELISA would be a next generation tool offering greater sensitivity, smaller reagent volumes and 
shorter incubation times unlike the traditional ELISA. With the advantage of microfluidics, it is 
easier to adapt this method to multiplexed detection of proteins. It can also adapt to the 
smartphone integration tool which is currently being used with many gold standard methods 
cutting down on infrastructure like in hospitals and centralized laboratories. In our approach of 
protein detection our applied technique would eliminate the need for complexed engineering 
devices and give it an advantage of smaller sized device with greater sensitivities, reduction in 
the costs, and high detection sensitivities. In order to prove this concept, we used 4 protein 
biomarkers which had detection limits in the femtogram range. The dynamic ranges of these 
were wider in comparison with the plate- based ELISA’s. A recovery of 92% to 108% was obtained 
from spiked human serum samples, with a standard deviation of less than 5%. Colorimetry using   
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tetramethylbenzidine (TMB) and chemiluminescense using luminol as enzyme substrates was 
demonstrated too in this approach.  
 
3.2. Introduction  
 
Scheme 3.1. General scheme of the Sandwich Immunoassay protocol for ELISA based assays 
 
ELISA is an analytical biochemical assay used for the detection of an analyte usually an 
antigen, antibodies, proteins, and other molecules from complex matrices like blood 
serum.69,70,71 ELISA has commercial applications in fields like biomedical research, forensics and 
medicine and clinical studies and also utilizes the detection of just one biomarker at a time in a 
96 well plate which is nothing but a polystyrene microtiter plate. Because of this wide range of 
applications, it was considered a gold standard for quantification of the analyte.67 Being the gold 
standard has made the ELISA the most reliable method, however it has failed in addressing the 
requirements of point of care diagnostic testing which is an upcoming field. It fails as it is   
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Antibody 
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Immuno ssay 
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expensive, with large size of the instrument involved for detection and quantification, and also 
operational expertise is required.72 For the above it can be easily concluded that in order to 
improve the performance of ELISA and adapt it to POC diagnosis the microwell plate based assay 
needs to be modified adapting to microfluidics making it possible to detect multiple biomarkers 
effortlessly.72 Currently lateral flow strips are being used successfully for POC immunoassays. 
However, these lateral flow strips are limited to qualitative and semi quantitative assessment.73 
In this view modifying the ELISA to meet the needs of POC diagnostics by miniaturizing it and for 
effective qualitative and quantitative assessment would be a breakthrough in the world of POC 
testing.  
Lab-on-a-chip (LOC) has been an upcoming platform which is being used in order to 
introduce microfluidics to any desired assay in use.74, 75 This has been a major advancement in 
transforming other centralized labs to meet the need of POC testing.75 The basic characteristics 
associated with LOC include small size, small reagent and sample volumes, and rapid analysis. It 
is these parameters put together making the concept of LOC ideal for POC testing. Currently some 
operator expertise techniques have been employed to fabricate LOC devices.76 These techniques 
include lithography,77 soft lithography,78 micro machining and milling,79 and polymer molds80 
etc., which were considered reliable but have very bulky instruments. With the recent discovery 
and the wide use of 3D printing technology has increased the opportunity for creating improved 
bioanalytical devices that can be used for many applications.81 It has offered great advantages 
like low cost of printing, ease of making complex designs using a simple computer aided design 
(CAD) software and has minimum effort post processing. Fields like electronics,82 drug delivery,83 
sensors for physiological analytes in body fluids,84, 85 protein detection,86, 87 DNA toxicity,88   
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molecular diagnostics and even scaffolds and prosthetics89 have been explored by researchers 
with respect to incorporation of the 3D printing technology.  
In diagnostic applications where results are expected to be quick, 3D printing along with 
the use of smart phones has been suggested which gives better results even in poor resource 
settings. In this view ELISA being one of the most used assays in diagnostic testing, several 
attempts have been made to modify the assay to adapt it to lab-on-a-chip idea. Thus, improving 
the sample and reagent handling, the cost, the size, better reaction kinetics, allows detection of 
single to multiple biomarkers.  This makes them better detection methods/ systems. Other 
significant improvements aimed at developing strip microtiter plates and low microwell density 
plates with 2, 6, 8, and 12 wells instead of the standard 96 well plates being used for partial plate 
analysis. Like 96 well plates strip plates have the disadvantage of contamination due to reusability 
and the inconvenience of handling. Thus, arises the need to find an alternative with a 
microfluidics platform being able to design the number of desired microwells and use them for 
some modified ELISA methods but using simpler equipment. Smartphones are handy and 
available with every individual today. The idea about the use of smartphones in sensors offers an 
opportunity to POC testing in a limited resource environment. Their use in smartphone-based 
biosensors today is just to convey or communicate the information that is in other terms as a 
read- out device. They have the advantages of affordable, easy and safe to handle by all, state of 
the art imaging capabilities with cameras built-in making them most suitable for POC testing. 
Currently smartphones are being used in bioanalytical testing especially in disease diagnostics 
where a simple yes or no result does not offer a reliable answer. Researchers have successfully 
used smartphones in several such bioanalytical applications employing simple imaging for   
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colorimetric detection90, 91, 92 or adapting to some additional features that would help detection 
through chemiluminescence or fluorescence.93, 94, 95, 96  
In our study we show a simple, electronic and high-end equipment free, low technology 
but smartphone interfaced 3D printed array utilizing colorimetric and chemiluminescence 
detection of protein cancer biomarkers. The ELISA assay performed in a 3D printed tip serves as 
a replacement for the traditional low density 96 microwell plate giving rapid, improved and 
sensitive detection. The new and modified design uses a regular pipette and a smartphone with 
a commercially available software and a 3D printer giving the entire concept the base of a 
microfluidic system to yield better sensitivities than traditional ELISA in a plate. We also showed 
the simultaneous detection of 4 biomarkers namely Vascular Epithelial Growth Factor (VEGF), 
IGF-1, IGFBP3, and CD-14 on an 8- channel pipette tip array with detection limits ranging from 25 
pm mL-1 to 500 fg mL-1. The method was validated by using spike samples and checking their 
recoveries in human serum. The recoveries were within the acceptable limit of ±20 %. 
 
3.3. Experimental section 
3.3.1. Chemicals and Materials 
Chitosan (Analytical Grade) (Low molecular weight) and Glutaraldehyde were 
bought from Sigma Aldrich, Casein used as the blocker in PBS from Thermo Fischer, ELISA kit 
for Prostate Specific Antigen (PSA)97(DKK300), Vascular Endothelial Growth Factor (VEGF)98 
(DEV00) brought from R&D Systems, R&D Systems substrate reagent pack was used for the 
generation of Colorimetric assay, while the chemiluminescence assay was developed using 
the reagent pack from Thermo Fisher Supersignal® west femto chemiluminescent substrate.  
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The image processing of the results was done using an iPhone or android smartphone that is 
compatible with the application Loomatix Color Grab®. 
 
3.3.2. Fabrication of the 3D printed tips 
 
Figure 3.1. Model representations of the ELISA tips as designed by Dr Karteek. Kadimisetty (A) 
Shows a single pipette ELISA tip array, with the side view indicating the direction of flow of 
reagents from bottom into the immunoassay chamber with pressure applied by a pipette that 
is attached at the pipette housing on the top. (B) Front view of the printed tip, immunoassay 
chamber as a viewing window where the colorimetric /chemiluminescent assay takes place. 
Inset is the sandwich immunoassay occurring on the inner surface of immunoassay chamber. 
(C) A Multi-chamber pipette ELISA tip used via a multichannel pipette for multianalyte or 
multiplex detection. 
 
The computer aided design of the ELISA tips was done using 123Design software by 
Autodesk. Clear photocurable resin (FGCL02) which was purchased from Formlabs was used 
in a Formlabs Form2 3D printer to print the tips. The design is very simple and consists of a 
single chamber for the detection, an inlet portion and a dead volume portion on either side 
of the detection chamber or the immunoassay chamber. The sample or reagent inlet acts as 
a tube to help the drawing in of the reagents into the immunoassay chamber which acts as   
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the detection chamber by the use of a normal laboratory pipette. So thus, the other end of 
the ELISA tip is designed such that it can adapt or fit in the regular lab pipette in order to suck 
in the sample and reagents. Fig 3.1 A &B very clearly show this design. Beyond the 
immunoassay chamber is a small space left for dead volume which also extends to an extra 
reservoir space in order to prevent contamination of reagents and sample with the pipette. 
The total volume of the tip thus is kept to be 50 ±3 μL., of which the immunoassay chamber 
has a volume of 45 μL while the rest is dead volume. Pipetting 50 μL of sample and reagent 
volumes ensures filling up of the entire immunoassay chamber each time reproducibly. The 
end of the tip where the pipette fits in is designed to fit in standard 100 and 200 μL pipettes. 
Each tip is 0.27ʺ in width and 2.07ʺ in length. The signal generated inside the immunoassay 
chamber of the pipette tip can be easily observed due to its available transparency. For 
multiple analyte or sample analysis an 8 channel multi chamber pipette tip is presented. This 
can be used with an 8 multi- channel pipette Fig 3.1 C and 3.2A. represent the entire set 
designed to fit the multichannel pipette has the dimension of 2.85ʺ in width and 2.07ʺ in 
length which is the same as a single tip designed.  
The CAD file design is first converted to .stl file which makes it printer compatible via 
preform software. The software allows us to rightly orient the objects and print multiple 
objects at the same time. About 50 tips can be printed in a single batch. Thus, the cost to 
print a single tip array is just $0.07 with a print time of 8 min/ array approximately. On the 
other hand, the multi- chamber pipette tips printed were 16 per batch making the cost $2.50 
per array taking 55 min/ array. Once the printing has been completed the objects are 
removed for the printer stage and washed and sonicated with isopropanol in order to remove   
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the excess uncured resin. They are then air dried and sprayed with acrylic clear coat spray 
(KrylonTM) making them optically transparent and thus, suitable for colorimetric and 
chemiluminescence detection. 
3.3.3. Immunoassay protocol 
 
Figure 3.2. General scheme of the standard sandwich immunoassay taking place on the inner 
ELISA tip wall as designed by Dr Karteek. Kadimisetty with predictions for post sandwich 
immunoassay. (A) Fully transparent 8 chamber 3D printed tip array filled with four different 
color food dyes representing 4 different protein biomarkers chosen, loaded using a 
multichannel pipette. (B) Schematic representation of the pre-coating reaction steps for the 
immobilization of capture antibodies on immunoarray tip wall followed by the sandwich 
immunoassay and signal generation for colorimetry and chemiluminescence. 
(C)Representation of the steps for signal capture after the signal generation and its processing 
using a smartphone and microplate reader for application in both centralized labs & POC 
analysis. 
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3.3.3.1. Coating of Primary Capture Antibody on the inner walls of the microfluidic Tip 
array 
In the first step of the assay the walls of the ELISA Tip need to be coated with 
antibodies. This is done via chitosan activated glutaraldehyde cross linking.99, 100 1% 
Chitosan at pH 4.0 is first taken inside the immunoassay chamber pipetting 50 μL of the 
reagent and incubating it for 2 hours at room temperature. The Chitosan forms a uniform 
coating on the inner walls of the chamber and provides active amino acid groups, Fig 3.2B. 
The excess chitosan is removed by draining without washing and then the tips are air dried 
under vacuum or heat dried for 10 min at 60 ºC. The ability of Chitosan to be retained and 
adsorbed on the polymeric inner surfaces of the immunoassay chamber of the tips has been 
reported to be good.99, 101 2.5% 50 μL of Glutaraldehyde prepared in PBS buffer pH 7.4 is 
then pipetted into the immunoassay chamber and incubated for 90 min followed by 
washing twice with PBS Buffer. Serially after washing 10 μg mL-1 of capture antibody is then 
pipetted in and allowed to coat by incubation inside the chamber for 3 hours at RT or 
overnight at 4 ºC. Here the amine groups of the antibodies are allowed to crosslink with the 
aldehyde groups that ate already present on the inner surface of the tip chamber provided 
by the Chitosan coating, Fig 3.2B. There is uniform coating of the antibodies all over the 
inner walls of the chamber due to this process of pipetting and incubation of the reagents 
serially. The excess capture antibodies that are not covalently attached to the surface are 
then drained and washed three times with PBS Buffer containing Tween 20 pH 7.4. 1% 
Casein is then pipetted into the tip chamber and allowed to incubate for 1 hour at room 
temperature, this is done to avoid non- specific binding. This step is followed by washing   
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once again with PBS + Tween 20 buffer, pH 7.4. The 3D printed tip has now been successfully 
coated with capture antibodies on the inside and can be stored at 4 ºC prior to use and are 
stable for 4 weeks. 
 
3.3.3.2. Assay Procedure 
The Immunoassay is based on simple standard sandwich immunoassay. 
Undiluted calf serum used as a surrogate for human serum is diluted approximately in 
Eppendorf tubes or a 3D printed 8 well sample holder, Fig.3.3 B. 
 
 
Figure. 3.3. (A) Photographic representation of ELISA in a single tip array, printed and filled 
with different colored food dyes. (B) Multi chamber/ 8 chamber ELISA in a tip platform, printed 
and filled with colored dye indicating 4 different biomarker detection. Inset 8 well 3D printed 
add-on for use in multi analyte analysis. (C) A non- transparent chamber designed for CL 
detection that blocks unwanted CL from the sampling conduit and dead volume conduit 
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This acts as the control which is followed by coating with the target analyte biomarker 
protein from serum samples and incubated 30 min followed by draining and washing once 
again with PBS + Tween 20 buffer twice. Finally, the target specific biotinylated detection 
antibody was pipetted into the microfluidic immunoassay chamber of the tip, followed by 
incubation for 20 min and then the solution is drained and the tip is washed with PBS + 
Tween 20 buffer 2 times. Streptavidin HRP (Horse radish peroxidase) was finally pipetted 
into the tip and incubated for 15 min followed by washing 2 times with PBS + Tween 20 
buffer. In the last step of the assay enzyme substrate TMB+ H2O2 was pipetted into the 
tips and incubated for just 10 mins. A blue color is seen to develop. At this point 
smartphone images were taken for onsite analysis. Alternatively, the colored reaction 
mixture was transferred to a microtiter plate that contains the stop solution of 0.2M 
H2SO4. As soon as they are transferred in to the wells of the microtiter plate containing 
H2SO4there is a color change from blue to yellow, which is detected measuring the 
absorbance at 450 nm on a plate reader Fig 3.2C.39  
 
Scheme. 3.2 Colorimetric Signal Generation; TMB 
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In case of Chemiluminescence detection, the same sandwich immunoassay procedure is 
followed except SuperSignalTM West Femto maximum sensitivity chemiluminescent enzyme 
substrate is used. This gave the chemiluminescence signal that is measured using a CCD 
camera for 120 sec integration time in a dark box. 
 
Scheme 3.3 Chemiluminescence signal generation, Luminol 
 
3.3.3.3. Image processing via commercial smartphone- based app 
Commercially available Loomatix color grab which is a free app that is both 
android and iPhone friendly was used to integrate the colorimetric signal obtained from 
the assay. Color grab as the name suggests is a portable color digitizer within built tools 
to read color intensity and its shades accurately from a live captured image.102 The images 
captured are opened in the app and once opened and locked using the lock function 
enable the color picker tool. Pointing to a frame in the image of the signals from the 
immunoassay generates conversion values for the frame that has been selected. The 
conversion window displays multiple analytics for the selected frame by the user, these 
include color and color formats, lightness and darkness percentage values, greyscale. The   
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greyscale color analysis most importantly gives the slight difference in the colors. Red/ 
Blue/Green (RBB), hue/saturation/value (HSV), hue/saturation/ lightness (HSL), 
lightness/A(green-red)/B(Blue-yellow) (LAB) and cyan/magenta/yellow/black (CMYK) are 
the options that can be explored for further analysis. Evaluating all of these above values 
the K% value was observed and found to be consistent with a significant change in 
concentration. 
 
3.4. Results 
3.4.1. Reproducibility 
The precision of the assay was checked by running each of the concentrations 
three times (n=3) for both the colorimetric and the chemiluminescent assays as seen in Fig 
3.4 A&D. Fig 3.4 A shows the reproducibility of the colorimetric assay in which the signals 
were obtained from 4 different single pipette ELISA tips with the concentrations of 1.3 and 
12 ng mL-1 of VEGF in undiluted calf serum. The Figure 3.4 D on the other hand shows the 
signal reproducibility for chemiluminescent assay from 3 single ELISA tips using 1 and 10 ng 
mL-1 PSA in undiluted calf serum. The standard deviations were calculated for each of the 
analyzed concentrations and were observed to be <7%. This value indicated good 
reproducibility. Inter- day standard deviations were checked for by repeating the same 
experiments over a 3- day period for specific concentrations. The standard deviations 
calculated in this case were observed to be <5%.  
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3.4.2. Single biomarker detection using “ELISA in a Tip” platform  
Calibration curves for single biomarkers were first established by running different 
concentrations of VEGF for the colorimetric assay and that of PSA for the chemiluminescent 
assay all done in undiluted calf serum. The signals obtained from the colorimetric assay were 
generated using commercial ELISA TMB substrate. In this assay equal volumes of TMB and 
peroxide substrate were mixed that is 1:1 ratio and in the presence of Horse radish 
peroxidase (HRP) the colorless TMB substrate gets oxidized into blue colored 3, 3’, 5, 5’ 
tetramethylbenzidine diamine (Structure given in Scheme 3.2) in a manner that is dependent 
on the concentration of HRP. The blue color developed is read directly in a smartphone-based 
quantitation app or the reaction can be quenched after 10 mins by the addition of 0.5 N H2SO4 
and then measuring the absorbance at 450 nm.  
Fundamentally the ELISA in a tip assay was to prove enhanced immunoassay tool 
without the need for major changes in the currently used immunoassay. But with the view to 
show the adaptability of our approach to POC diagnostics, this was showed using the 
smartphone- based detection that is used for onsite analysis of samples and taking a simple 
photograph which is integrated using the commercially available color analytics app named 
Color Grab. (Fig. 3.5.) 
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Figure 3.4 Showing results of a single tip assay for both colorimetry and chemiluminescence 
detection systems. (A) Reproducibility of the colorimetric detection n=4 for biomarker 
protein VEGF in undiluted calf serum for 2 different concentrations of 1.3 ng/mL and 12 ng/ 
mL. (B) Colorimetric assay showing the distinctive change in color intensity with the 
concentration of VEGF protein biomarker. (C) Calibration curve plotted after the analyzing 
data using the smart phone image and app. (D) Raw CL images captured via CCD camera 
showing the reproducibility of results n=3 for two different concentrations of PSA 1ng/mL 
and 10 ng/mL. (E) Recolorized CL images. (F) Calibration curve for concentration of PSA 
against the CL intensity. 
 
The results thus obtained can then be interpreted to draw the necessary 
conclusions. For the single ELISA tip assay VEGF was used as test protein and form the data 
obtained calibration curves were developed followed by spike and recoveries in order to 
prove the accuracy of the method we developed in human serum using a smartphone for 
analysis. Fig 3.4 A&B show the images of the colorimetric assay after 10 mins of reaction of 
TMB + H2O2 (1:1) at different concentrations of the tested protein, VEGF here. The mobile 
phone images taken in the above assay before stopping the reaction with sulfuric acid were 
analyzed with the Color Grab app. From the images it was clear that the intensity of the blue 
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color increases with the increase in the concentration of VEGF (Fig 3.4 B). The detection limit 
for VEGF was 50 pg/mL and the dynamic range was 50 pg/mL to 10 ng/mL. The plot of the 
color intensity (%K values) plotted Vs the known concentration of VEGF is given by Fig 3.4C. 
With the help of the plot spike and recovery tests in human serum gave good accuracy w.r.t 
to the developed method. The % recovery obtained was seen to be between ± 20% given in 
Table 3.1.  
 
 
Figure 3.5. Screen shots from a smartphone showing images for color analysis of the ELISA in 
a Tip array using the app. Interpretation of the results was done by Dr. Karteek Kadimisetty. 
(A) Simple stepwise color analysis from an image of the tips after the assay to picking color to 
provide color analytics. (B) Color analysis of sample output for a tip array as a part of 
reproducibility experiments and highlighted in the red circles is showing the selected 
parameter of developing calibration curves 
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Table 3.1. Summary of Spike and recovery results from single and multiplex immunoassay 
using spiked human serum samples 
Technique Protein 
Biomarker 
Spiked 
Concentrations 
(pg/mL) 
Found 
Concentration 
(pg/mL) 
% Recovery 
Mobile phone 
analysis 
Single Tip Arrays 
VEGF 
100 106.9 (± 6) 106.9 (± 7) 
1000 949.6 (± 84) 95.0 (± 9) 
4000 4133.2 (± 454) 103.3 (± 7) 
Colorimetric 
analysis 
8 chamber Tip 
Array 
PSA 
20 21.1 (± 1.5) 105.3 (± 7) 
300 296.8 (± 38.5) 98.9 (± 13) 
2000 2397.6 (± 144) 119.9 (± 6) 
VEGF 
125 122.9 (± 15) 98.4 (± 12) 
500 436.3 (± 42) 87.3 (± 9) 
2000 2051.7 (± 287) 102.6 (±14) 
IGFBP-3  
20 18.7 (± 2.1) 100.9 (± 11) 
200 197.2 (± 19.8) 98.5 (± 10) 
2000 1878 (± 226) 93.9 (± 12) 
CD-14 
10 11.4 (± 0.89) 113.6 (± 7) 
500 450.8 (± 43.1) 90.2 (± 9) 
5000 5402 (± 486) 108 (± 9) 
 
Note: The concentrations are given after the subtraction of the control human serum 
concentration 
 
The results of the chemiluminescence assay using CCD camera for detection is 
demonstrated using PSA as the test protein and using Supersignal® west femto reagent along 
with luminol and peroxide that are mixed in a ratio specified by the manufacturer and then 
followed by incubation within the tip to complete the assay. Luminol is oxidized to its excited 
state in the presence of HRP, it then relaxes to the ground state emitting light that is captured 
and integrated over 120s in a dark box using a CCD camera. The figures 3.4 D & E show 
changes in the chemiluminescence intensities changing with change in concentration of PSA 
in undiluted calf serum. The calibration curve is plotted for the relative signal intensities 
obtained for the different concentrations of PSA (Fig 3.4 F) against the respective 
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concentrations. The detection limit of 1 pg./ mL and the dynamic range from 1 pg./mL to 100 
ng/mL were obtained. 
Table 3.2: A comparative description between ELISA in a Tip Vs the microtiter plate ELISA 
Type of Comparison  ELISA in a Tip Traditional ELISA 
Assay Time   
Sample Incubation 
Detection Antibody 
Streptavidin- HRP 
Development & Quench 
Detection 
Approx. total wash time 
Total assay time 
30 min 
20 min 
15 min 
12 min 
2 min 
6 min 
5 min 
150 min shaking suggested 
60 min shaking suggested 
45min 
32 min 
2 min 
9 min 
298 min 
Reagent/ sample volume 50 μL sample 50 μL wash 150 μL sample 300 μL wash 
LOD (pg/mL) &  
Dynamic ranges (pg/mL) 
PSA – 5 & 5 -10000 
VEGF - 25 & 50 - 10000 
IGFBP - 3- 4 & 4 - 8000 
CD-14 - 0.5 & 1 - 10000 
PSA – 900 & 900-60000 
VEGF - 25 & 35- 2000 
IGFBP -3- 100 & 100- 8000 
CD-14 - 62 & 62- 4000 
Assay cost per microwell $ 1.2 (per pipette tip) $ 4.14 
Human PSAELISA kit - $398 
Smartphone integration Yes Yes 
Multiplexity Yes (using multi chamber 
pipette tips) 
N0 
 
3.4.3. Multiple biomarker in an 8 – chamber pipette tip array 
Using a multi chamber (8- chamber) tip array in our case and multi- channel pipette, 4 protein 
biomarkers were detected simultaneously. PSA, VEGF, IGFBP-3 and CD-14 are mixed together in 
undiluted calf serum in order to get a multiplexed sample. For proof of concept colorimetric 
detection was used and all the biomarkers showed a detection limit that was 10-100-fold lower 
along with an extended dynamic range as compared to conventional ELISA (Table 3.2)   
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The assay protocol remains the same as that of a single tip assay. The only 
difference is that here 8- chamber 3D tip array is used in which the multiplexed sample 
and the reagents were simultaneously pipetted using an 8-channel pipette. Following the 
sample steps of incubation and washing the colorimetric signal was then generated using 
enzyme substrate. For sample analysis a 3D microwell add on was printed which consists 
of 8 wells and has a capacity of 60 μL ,Figure 3.4. Since one of the many goals of the 
project was to replace the standard plate- based assay with microfluidic tip array for 
higher sensitivity and additional benefits of multiplexing, standard detection method of  
absorbance with a plate reader is being used to meet the target. The absorbance of the 
respective reactions is measured after quenching with 0.5 N sulfuric acid which is then 
plotted against the concentration of the protein under study. The calibration curves thus 
obtained (Fig: 3.4) with n=4 for each of the markers showed a detection limits of 5 pg/mL 
for PSA, 25 pg/mL for VEGF, 4 pg/mL for IGFBP-3 and 0.5 pg/mL for CD-14 using the 
detection limits to be 3 times the standard deviation of the zero-protein concentration of 
the control. The Dynamic ranges of 5 to 10000 pg/mL for PSA, 50 to 10000pg/mL for VEGF, 
4- 8000pg/mL for IGFBP- 3 and 1 to 10000 pg/mL for CD-14. 
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Figure 3.6. Shows calibration plots from the data obtained from multiplexed detection of 4 
biomarkers simultaneously using multi-chamber tip array and multichannel pipette in a plate 
reader as per the data collected by Dr. Karteek. Kadimisetty and Mohammed Sharafeldin. (A) 
PSA (B) VEGF (C) IGFBP-3 (D) CD-14. 
 
The percentage recoveries for spiked samples in human serum were calculated using 
the multiplex calibration curves (Fig 3.6). The recovered concentrations were 
calculated by subtracting the control concentration that is with no spiking. All the 
biomarkers studied showed recoveries varying from 80 to 120 % with standard 
deviations less than 15%. These were also indicative of the accuracy of the assay in 
complex matrices like human serum. 
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3.5. Discussion 
The results obtained by carrying out the traditional assay with modifications like 
using 3D printing, microfluidics, smartphones and common lab tools like pipettes help gave a 
new outlook with better results for diagnostic testing practices. Transforming the standard 
ELISA to the modified ELISA in a tip we were able to demonstrate sensitive detection of 4 
cancer biomarker proteins simultaneously which acts as a possible prostate cancer biomarker 
panel at a very low cost and reduced assay time. The proposed ELISA tip assay has a nothing 
but a 3D printed pipette tip similar to a conventional pipette tip with a modified chamber 
where the immunoassay is being carried out. The conventional ELISA also involves removing 
the pipette tips several times as compared to the microfluidic platform where the tip remains 
attached to the pipette carrying out the sandwich immunoassay. The total assay time is 
reduced by about 90 mins in comparison to 300 min (Table 3.2) which is the assay time 
required for a conventional ELISA. The cost of the assay per tip array is calculated to be $1.20 
as compared to the cost of traditional ELISA which is $4.1 approximately (Table 3.2). The use 
of 3D printed microfluidic tip and the reduced reagent and sample volumes help in the 
reduction of the cost per assay. The capacity of the tip is 50 μL  compared to traditional 
microtiter plate microwells whose capacity is 100 to 300 μL. Kinetic studies of the interaction 
between antigen and antibody is important and is considered as a factor that could affect the 
sensitivity of the assay and the time of ELISA. Limitations of conventional ELISA include that 
the concentration of capture antibodies is low as they are immobilized only at the bottom 
and side walls of the microwells and also this increases the stearic hinderance.103, 8. On the 
other hand, our pipette tip ELISA assay has advantages over these limitations where the   
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immobilization of the capture antibodies is on all four sides of the camber giving the assay 
greater sensitivity, also the miniaturized chamber helps to increase the reagent volume to 
surface area ratio which is estimated to be 131 μL /cm2 and 31 μL/ cm2 for the microwell 
plate and the pipette tip chamber assays respectively. It is seen that the volume to surface 
area ratio is lowered 4 times which helps in drastically improving antigen- antibody 
interaction kinetics giving better sensitivity and shorter assay times. An additional advantage 
was that the designed system allows the users with basic pipetting skills to be able to run the 
assay without requiring complex and equipment.  
The design of the pipette tip with the advantage of them being see through with a 
wide detection chamber gave them ability to adapt to different detection systems that can 
thus be used in places with limited resources countering the need for traditional ELISA plate 
readers. The 3D printed optically transparent pipette tip which is a microfluidic platform was 
seen to work for both colorimetric and chemiluminescent signal detection. 
Chemiluminescent assays were successfully demonstrated using PSA from blood serum with  
detection limits of 1 pg/mL. The simple CCD camera was used for the detection instead of the 
plate reader being used as for the detection based on the absorbance. Simple modifications 
in the design for “ELISA in a Tip” could perform both multiple analytes and multiple sample 
assays simultaneously (Fig 3.3 A). 8- chamber pipette tip array was designed, printed and used 
for running 8 sandwich immunoassays simultaneously. These together efficiently detected up 
to 4 cancer biomarker proteins at the same time with n= 2. The smartphone interfacing was 
also used for limited setting diagnostic testing which had installed the free, commercially 
available color analyzing color grab software showing the sensitive interpretation and   
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differentiation of colorimetric signal. The results were validated using spiked samples in 
human serum. With its goal to meet POC testing applications the use of smartphones helps 
in telemedicine and also establishes a network between assay technician, centralized labs 
and physicians. The detection of multiplexed markers and their accurate quantitation is 
crucial for the confirmative disease diagnostics especially on cancer. ELISA is still the gold 
standard for single marker detection and quantitation but, in countries where the resources 
are scarce the approach with the use of smartphones the new technology can be made 
available to crowds over all at affordable costs to improve healthcare.  
3.6. Conclusion 
Simple and innovative “ELISA in a tip” immunoassay was successfully developed and 
validated. 3D printing technology was used for making the tips for this purpose was less complex 
method that was seen to improve the detection limits, dynamic range at a low cost, low sample 
volumes, reduced assay time and reduced complex operating. This simple and innovative design 
was a breakthrough for multiple detection strategies and multiplexed detection. The added 
smartphone integration enabled the prospect of the technology being used for POC diagnostics 
and telemedicine. While it reduced the assay time to as close to 90 mins. The ideal scenario would 
be less than 30 mins.8 The aim of our method was not to change the method of the standard 
ELISA as being currently used in the industry but given an improved method with the latest 
technology that can be adapted easily. This was done with the aim of reaching the ultimate goal 
of creating futuristic platforms for immunoassays that give better access to better health 
universally.   
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